Bortezomib for refractory antibody-mediated cardiac allograft rejection.

Peter M Eckman; Marit Thorsgard; David H Maurer; Youngki Kim; Rita R. Alloway; E. Steve Woodle

Bortezomib for refractory antibody-mediated cardiac allograft rejection.

Peter M Eckman, Marit Thorsgard, David H Maurer, Youngki Kim, Rita R. Alloway, E. Steve Woodle

Research output: Contribution to journal › Article › peer-review

Abstract

This experience demonstrates that a bortezomib-based regimen provided effective therapy for late, refractory AMR in an adult heart transplant recipient and was well tolerated. This remarkably positive experience despite the refractory nature of the AMR episode argues strongly for continued evaluation of bortezomib use in this patient population.

Original language	English (US)
Pages (from-to)	475-478
Number of pages	4
Journal	Clinical transplants
State	Published - 2009

Find It

Find It at U of M Libraries

Cite this

@article{43251ae661624715b21337b51e862228,

title = "Bortezomib for refractory antibody-mediated cardiac allograft rejection.",

abstract = "This experience demonstrates that a bortezomib-based regimen provided effective therapy for late, refractory AMR in an adult heart transplant recipient and was well tolerated. This remarkably positive experience despite the refractory nature of the AMR episode argues strongly for continued evaluation of bortezomib use in this patient population.",

author = "Eckman, {Peter M} and Marit Thorsgard and Maurer, {David H} and Youngki Kim and Alloway, {Rita R.} and Woodle, {E. Steve}",

year = "2009",

language = "English (US)",

pages = "475--478",

journal = "Clinical transplants",

issn = "0890-9016",

publisher = "UCLA Immunogenetics Center",

}

TY - JOUR

T1 - Bortezomib for refractory antibody-mediated cardiac allograft rejection.

AU - Eckman, Peter M

AU - Thorsgard, Marit

AU - Maurer, David H

AU - Kim, Youngki

AU - Alloway, Rita R.

AU - Woodle, E. Steve

PY - 2009

Y1 - 2009

N2 - This experience demonstrates that a bortezomib-based regimen provided effective therapy for late, refractory AMR in an adult heart transplant recipient and was well tolerated. This remarkably positive experience despite the refractory nature of the AMR episode argues strongly for continued evaluation of bortezomib use in this patient population.

AB - This experience demonstrates that a bortezomib-based regimen provided effective therapy for late, refractory AMR in an adult heart transplant recipient and was well tolerated. This remarkably positive experience despite the refractory nature of the AMR episode argues strongly for continued evaluation of bortezomib use in this patient population.

UR - http://www.scopus.com/inward/record.url?scp=77954614876&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77954614876&partnerID=8YFLogxK

M3 - Article

C2 - 20524318

AN - SCOPUS:77954614876

SN - 0890-9016

SP - 475

EP - 478

JO - Clinical transplants

JF - Clinical transplants

ER -

Bortezomib for refractory antibody-mediated cardiac allograft rejection.

Abstract

Find It

Other files and links

Fingerprint

Cite this